Hybrid LC-MS/MS Technology Becoming the New Norm in the Bioanalysis of Antibody-Drug Conjugates -- Examples and Case Studies, Upcoming Webinar Hosted by Xtalks
TORONTO, May 6, 2024 /PRNewswire-PRWeb/ -- Recently, the role of hybrid liquid chromatography-mass spectrometry (LC-MS/MS) in the analysis of antibody-drug conjugates has increased due to the complexity and number of bioanalytical assays needed to support this modality in the drug development process. Antibody-drug conjugates tend to consist of a toxic small molecule payload attached via a linker to an antibody. The application of these drugs had mainly been in oncology where their mode of action is for the antibody to attach at the desired target site with subsequent release of the small molecule to combat tumor cells.
- Antibody-drug conjugates tend to consist of a toxic small molecule payload attached via a linker to an antibody.
- Hybrid LC-MS/MS can easily be used to monitor both the total antibody as well as the antibody-drug conjugates.
- At the very least, the availability of hybrid LC-MS/MS as an alternative technology greatly increases the chances of success in the bioanalysis of antibody-drug conjugates.
- Register for this webinar today to get an overview of the bioanalysis of antibody-drug conjugates.